Depot-Medroxyprogestereone Acetate
ApprovedSmall molecule
Depot-Medroxyprogestereone Acetate is one of 67 small molecule programs targeting Contraception. It is currently in Approved.
2
Indications
3
Total Trials
0
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
102 competitors in Contraception
#DrugCompanyPhaseTrials
1Carbocaine
PfizerPhase 3
Depo-Provera
Eli LillyPhase 3
Feldene
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Estradiol Valerate
BayerPhase 3
Yasmin
BayerPhase 3
Mirena
BayerPhase 3
Depot-Medroxyprogestereone Acetate
UUniversity of Southern California
Approved
Opill
LLaboratoire français de Fractionnement et de Biotechnologies
Phase 3
Norethindrone Acetate
WWatson Pharmaceuticals
Phase 3
Marvelon
BayerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details